Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over Trial to Assess the BE of Orvical 200 mg/50 mg FT in Comparison With Kaletra 200 mg/50 mg FT in Healthy Male Subjects Under Fasting Conditions

NCT04386876 is registered in ClinicalTrials.gov with World Medicine ILAC SAN. ve TIC. A.S. as lead sponsor.

NCT NCT04386876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04386876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over Trial to Assess the BE of Orvical 200 mg/50 mg FT in Comparison With Kaletra 200 mg/50 mg FT in Healthy Male Subjects Under Fasting Conditions
Lead sponsor
World Medicine ILAC SAN. ve TIC. A.S.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2020
Completion date
June 11, 2020
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence